February 13, 2025
´ºÓêÖ±²¥app School of Medicine
´ºÓêÖ±²¥app Hospital
Toward Developing the World's First Vision-Restoring Therapeutic Agent
In a company-sponsored clinical trial of "RV-001," a vision-restoring therapeutic agent developed by Restore Vision Inc. based on joint research between the Department of Ophthalmology, ´ºÓêÖ±²¥app School of Medicine and the Nagoya Institute of Technology, the first patient was dosed on February 6, 2025, at ´ºÓêÖ±²¥app Hospital.
This clinical trial aims to evaluate the safety and exploratory efficacy of "RV-001" in patients with severe retinitis pigmentosa, a hereditary retinal disease. The treatment involves administering the agent via a minimally invasive, non-surgical intraocular injection, and will be carefully evaluated over a follow-up period of approximately six months.
This clinical trial, led by Restore Vision Inc., a startup originating from ´ºÓêÖ±²¥app, bridges the gap from basic research to clinical application based on the joint research outcomes of both universities. "RV-001" represents an effort to become the world's first commercialized vision-restoring therapeutic agent and is a significant step toward providing a new treatment for blinding diseases.
For the full press release, please see below.